Drug Toxicity
miRNAs are known to play important roles in the diagnosis and prognosis of many cancers, and they are useful in developing targeted therapies.
Identification of novel molecular miRNAs and their target oncogenomic signatures have the potential to significantly impact clinical management.
Identifying patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product is a critical part of the development of personalized therapies.
Sensitive, specific and non-invasive biomarkers of cytotoxicity are required to help diagnose patients and also to identify safety liabilities during drug development
miRNAs could represent serum biomarkers capable of following patient progress reflecting drug toxicity effects such as liver injury or dysfunction.
Additionally, profiling miRNA biomarkers can provide insight into the basic mechanisms of cytotoxicity
Read more about how LC Sciences is helping clinicians and researchers with:
